
WALD Stock Forecast & Price Target
WALD Analyst Ratings
Bulls say
Waldencast is facing challenges due to the ongoing SEC investigation and caution towards the Milk Makeup segment, leading to lower revenue and earnings expectations for FY25. However, the company's strong performance in the Obagi Medical segment and ongoing strategic review to maximize shareholder value show potential for future growth. The recent credit agreement and sale of the Obagi Japan trademark rights also demonstrate efforts towards improving financial stability. Overall, the long-term growth potential of the company's brands and its consistent revenue generation from the North America region present a positive outlook for Waldencast's stock.
Bears say
Waldencast is facing several challenges that have contributed to a negative outlook on its stock. These include slower than expected growth in its Milk Makeup segment, with softer demand in international markets and inventory-related adjustments. In addition, the company's strategic review efforts have not yet yielded significant improvements in terms of profitability and market value. Finally, there are a number of industry-specific risks, such as volatility in commodity costs and the impact of geopolitical uncertainty, that could continue to hinder the company's performance.
This aggregate rating is based on analysts' research of Waldencast Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.
WALD Analyst Forecast & Price Prediction
Start investing in WALD
Order type
Buy in
Order amount
Est. shares
0 shares